The clinical relevance of drug–drug interaction between co-trimoxazole and sacubitril/valsartan treatment in a heart failure patient: a case report and overview of mechanisms and management in clinical practice
Explore this paper's citation graph
Summary
An interesting case of a patient presenting with hyperkalemia caused by the co-administration of LCZ696 and co-trimoxazole (sulfamethoxazoles/trimethoprim) is presented, highlighting the underlying pathophysiological mechanisms and the clinical approach to patients at risk of hyperkAlemia causing by the drug interactions with the novel therapy.
- Type
- dissertation
- Published
- 2018-01-15
- Cited by
- 3
- References
- 9
- Access
- Open access
- OpenAlex
- https://openalex.org/W29335802
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:11795560
Keywords
Electrolyte, Chemistry, Environmental science, Physical chemistry, Electrode
References
- Drug-Induced Hyperkalemia
- Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system.
- Angiotensin-neprilysin inhibition versus enalapril in heart failure.
- Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure
- Adherence to optimal heart rate control in heart failure with reduced ejection fraction: insight from a survey of heart rate in heart failure in Sweden (HR-HF study)
- Association of mineralocorticoid receptor antagonist use and in-hospital outcomes in patients with acute heart failure
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure